Haemophilus parasuis causes Glässser’s disease, a disease of significant economic impact in the pork industry.  Antimicrobial treatment is an important disease control option.  However, there are no accepted standardised methods for antimicrobial susceptibility testing of H. parasuis.  We are evaluating the capacity of a medium that has a known capacity to support good growth of H. parasuis to be used in disc diffusion (as an agar) and minimal inhibitory concentration (MIC) testing (as a broth).  To date, the medium (BA/SN) has been evaluated for use in disc diffusion.  Using the Clinical and Laboratory Standards Institute(CLSI) recommended guidelines and Quality Control (QC) strains, all five tested antimicrobials (ampicillin, ceftiofur, co-trimoxazole, florfenicol and tetracycline) have given the anticipated results across six independent repeats with Escherichia coli (with one exception when both the CLSI medium and the new medium gave an unacceptable result with ceftiofur).  For the Staphylococcus aureus QC strain, the new medium gave the correct results for seven antimicrobials (ampicillin, ceftiofur, erythromycin, florfenicol, tetracycline, penicillin and tilmicosin) but consistently gave an unacceptable result with co-trimoxazole. The preliminary results suggest that this new medium has the potential to be an acceptable medium for antimicrobial susceptibility testing for H. parasuis.